SEARCH:   Advanced

Blood, 1 January 2005, Vol. 105, No. 1, pp. 405-409. Prepublished online as a Blood First Edition Paper on June 10, 2004; DOI 10.1182/blood-2004-03-1103. This Article Full Text (PDF) All Versions of this Article: 2004-03-1103v1 105/1/405    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Garderet, L. Articles by Frassoni, F. Search for Related Content PubMed PubMed Citation Articles by Garderet, L. Articles by Frassoni, F. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted March 26, 2004 Accepted May 4, 2004 Hematopoietic stem cell transplantation for de novo acute megakaryocytic leukemia in first complete remission: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT) Laurent Garderet*, Myriam Labopin, Norbert-Claude Gorin, Emmanuelle Polge, Andre Baruchel, Giovanna Meloni, Juan Ortega, Jaak Vossen, Donald Bunjes, Guy Leverger, Didier Blaise, Augustin Ferrant, Mats Brune, Eric Dore, Helmut Gadner, Felix Zintl, Isaac Yaniv, Giorgio Dini, and Francesco Frassoni Acute Leukemia Working Party and Pediatric Working Party, European Group for Blood and Marrow Transplantation (EBMT), Paris, France International Transplant Center, University Paris VI, Paris, France International Transplant Center, University Paris VI, Paris, France; Hematology and Cell Therapy, Hopital Saint Antoine, Paris, France * Corresponding author; email: laurent.garderet{at}sat.ap-hop-paris.fr. Acute megakaryoblastic leukaemia (M7 AML) is a highly aggressive disease. We evaluated outcomes in 57 children (11 with Downs syndrome) and 69 adults with M7 AML after post first remission autologous or HLA-identical allogeneic transplantation. The characteristics of the autologous transplant recipients (38 children, 37 adults) were respectively: median age: 1.7, 46 years; non-total body irradiation (TBI) conditioning regimen: 97%, 70%; bone marrow as stem cell source: 74%, 43%. Those of the allogeneic transplant recipients (19 children, 32 adults) were: median age 2.8, 37 years; non-TBI regimen: 63%, 42%; bone marrow as stem cell source: 95%, 69%. Autologous transplants benefited children most; the relapse rate was high in adults. Results for autologous transplants were (children and adults respectively): engraftment (90%, 100%); 3-year treatment-related mortality (TRM) (3%, 8%); relapse rate (45%, 64%); leukemia-free survival (LFS) (52%, 27%); overall survival (OS) (61%, 30%). After allogeneic transplantation, TRM was fairly low in both children and adults and the relapse rates were lower than after autologous transplantation. Results for allogeneic transplants were: engraftment (95%, 90%); TRM (0%, 26%); relapse rate (34%, 28%); LFS (66%, 46%); OS (82%, 43%). We conclude that M7 AML patients in CR1 (except children with Downs syndrome who already have a better outcome) can benefit from transplants. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: Y. Oki, H. M. Kantarjian, X. Zhou, J. Cortes, S. Faderl, S. Verstovsek, S. O'Brien, C. Koller, M. Beran, B. N. Bekele, et al. Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center Blood, February 1, 2006; 107(3): 880 - 884. [Abstract] [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020